文献速递鼻科

丙酸氟替卡松与克拉霉素用于不同表型慢性鼻窦炎术后治疗的疗效比较:一项随机对照试验

Comparison of efficacy of fluticasone propionate versus clarithromycin for postoperative treatment of different phenotypic chronic rhinosinusitis: a randomized controlled trial.
PubMed 文献 · Rhinology · 2019-01-01

本研究为前瞻性单盲实效性试验,纳入187例中国慢性鼻窦炎患者,分层为不伴鼻息肉的慢性鼻窦炎(CRSsNP)及嗜酸性和非嗜酸性伴鼻息肉的慢性鼻窦炎(CRSwNP),随机接受丙酸氟替卡松鼻喷剂200微克或克拉霉素片250毫克每日一次,术后治疗3个月。结果显示两种药物在各亚型CRS多数随访点的症状和鼻内镜评分均无显著差异,补救治疗或难治性CRS的频率也无差异。

要点

  • 丙酸氟替卡松与克拉霉素在CRS术后治疗中疗效无显著差异
  • 研究覆盖CRSsNP及嗜酸性和非嗜酸性CRSwNP三种表型
  • 两种药物在症状评分、鼻内镜评分及补救治疗需求上均相似

核心结论

  • 在CRSsNP及嗜酸性和非嗜酸性CRSwNP患者术后治疗中,丙酸氟替卡松与克拉霉素疗效无显著差异。

研究设计与样本

  • 前瞻性单盲实效性比较试验,纳入187例中国CRS患者,按表型分层后随机分组。

主要发现

  • 两种药物组在术后各随访点总症状评分、单个症状评分、总鼻内镜评分及单个内镜域评分均较术前显著降低。
  • 在各CRS亚型中,两种药物在多数随访点的上述评分无显著差异。
  • 两种药物组接受补救治疗或发生难治性CRS的受试者频率无差异。

关键数值与推荐

  • 丙酸氟替卡松鼻喷剂剂量为200微克,克拉霉素片剂量为250毫克,均为每日一次,术后使用3个月。
  • 补救治疗采用口服泼尼松,在研究药物停用后给予。
  • 症状严重度采用视觉模拟量表由患者评分,鼻内镜表现由对治疗不知情的高年资医师根据EPOS 2012评分。
  • 评估时间点为ESS术前及用药后1、3、6、12个月。

临床怎么用

  • 对于CRSsNP及嗜酸性和非嗜酸性CRSwNP患者,术后可选择丙酸氟替卡松或克拉霉素治疗,两者疗效相当。
  • 可根据患者具体情况、耐受性和偏好个体化选择术后用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis (CRS) can be divided to CRS without nasal polyps (CRSsNP) and eosinophilic and non-eosinophilic CRS with nasal polyps (CRSwNP). There is little evidence on the efficacy of glucocorticoids and macrolides in different phenotypic patients. The aim of this study was to compare the benefit of glucocorticoids and macrolides following endoscopic sinus surgery (ESS) in different phenotypic CRS. METHODS: This study was a prospective single-blind comparative effectiveness trial. A total of 187 Chinese patients with CRS were stratified to CRSsNP and eosinophilic and non-eosinophilic CRSwNP group and then randomized to receive fluticasone propionate nasal spray at 200 microgram or clarithromycin tablet at 250 mg once daily for 3 months after ESS. Oral prednisone was given as a rescue therapy after the stop of study medication. Patients were assessed before ESS and 1, 3, 6 and 12 months after dosing. Symptom severity was scored by patients using visual analog scale method and endoscopic findings were scored by the senior physician blinded to treatment according to European Position Paper on Rhinosinusitis and Nasal polyps 2012. RESULTS: The total and individual symptom scores, and total and individual endoscopic domain scores were reduced significantly after ESS in both medication groups, whereas no significant difference was observed for two medications at most follow-up visits in each subtype of CRS. No difference in the frequency of subjects with rescue therapy or refractory CRS was found between two medication groups either. CONCLUSIONS: We could not show significant difference of effect between fluticasone propionate and clarithromycin in the post-operative treatment for CRSsNP and eosinophilic and non-eosinophilic CRSwNP patients.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Zeng M, Wang H, Liao B, et al. Comparison of efficacy of fluticasone propionate versus clarithromycin for postoperative treatment of different phenotypic chronic rhinosinusitis: a randomized controlled trial. Rhinology. 2019. PMID: 30136707. doi:10.4193/Rhin17.226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。